"3"^^ . . "CZ - \u010Cesk\u00E1 republika" . "Testov\u00E1n\u00ED HER-2/neu u karcinomu \u017Ealudku - nov\u00E1 v\u00FDzva i nad\u011Bje?"@cs . . . "Onkologie" . . . . . "Rozko\u0161, Tom\u00E1\u0161" . "HER-2/neu testing in gastric carcinoma - new challenge and hope?"@en . "3"^^ . "4" . . . "RIV/00179906:_____/10:10077876" . "Testov\u00E1n\u00ED HER-2/neu u karcinomu \u017Ealudku - nov\u00E1 v\u00FDzva i nad\u011Bje?" . "5"^^ . . . "Laco, Jan" . "Ry\u0161ka, Ale\u0161" . "[10738E1F5DAC]" . "Testov\u00E1n\u00ED HER-2/neu u karcinomu \u017Ealudku - nov\u00E1 v\u00FDzva i nad\u011Bje?"@cs . . "in situ hybridization; immunohistochemistry; c-erbB-2; HER-2/neu; Gastric carcinoma"@en . "292526" . "2" . . "HER-2/neu testing in gastric carcinoma - new challenge and hope?"@en . "V" . . "Testov\u00E1n\u00ED HER-2/neu u karcinomu \u017Ealudku - nov\u00E1 v\u00FDzva i nad\u011Bje?" . . "Karcinom \u017Ealudku je ve sv\u011Bt\u011B druhou nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na malignitu, proto se z\u00E1jem onkolog\u016F up\u00EDn\u00E1 k hled\u00E1n\u00ED nov\u00FDch prognostick\u00FDch a prediktivn\u00EDch marker\u016F. HER2 je u karcinomu \u017Ealudku negativn\u00EDm prognostick\u00FDm faktorem sdru\u017Een\u00FDm s vy\u0161\u0161\u00ED invazivitou, metastazov\u00E1n\u00EDm do uzlin a krat\u0161\u00EDm p\u0159e\u017Eit\u00EDm, i negativn\u00EDm prediktivn\u00EDm faktorem a c\u00EDlem pro biologickou l\u00E9\u010Dbu trastuzumabem. Existuj\u00ED dv\u011B metody detekce HER2 - imunohistochemie (IHC) a in situ hybridizace (ISH). Pozitivita HER2 se u karcinomu \u017Ealudku pohybuje v rozmez\u00ED 6,8-34% (pr\u016Fm. 17,6%) p\u0159i stanoven\u00ED IHC, resp. 7,1 - 42,6% (pr\u016Fm. 19,2%) pomoc\u00ED ISH. HER2 je \u010Dast\u011Bji p\u0159\u00EDtomen v intestin\u00E1ln\u00EDm typu karcinomu. P\u0159i stanoven\u00ED HER2 plat\u00ED n\u011Bkter\u00E1 specifika - za pozitivn\u00ED jsou pova\u017Eov\u00E1ny bu\u0148ky s kompletn\u00ED i s bazolater\u00E1ln\u00ED expres\u00ED proteinu, vzhledem k \u010Dast\u011Bj\u0161\u00ED nehomogenn\u00ED expresi je doln\u00ED hranice v resek\u00E1tech 10 % pozitivn\u00EDch bun\u011Bk, ale u endobioptick\u00FDch vzork\u016F je vy\u017Eadov\u00E1na p\u0159\u00EDtomnost alespo\u0148 jedn\u00E9 skupiny barv\u00EDc\u00EDch se (2+ nebo 3+) neoplastick\u00FDch bun\u011Bk."@cs . . . "Gastric carcinoma is second cause of cancer related death worldwide, therefore oncologists urge for identification of new prognostic and predictive markers. HER2 is in gastric cancer negative prognostic factor, associated with increased invasiveness, lymph node metastases and shorter survival, as well as negative predictive marker and target for trastuzumab treatment. There are two methods of HER2 detection - immunohistochemistry (IHC) and in situ hybridization (ISH). Positivity of HER2 in gastric cancer ranges from 6.8-34% (m. 17.6%) in IHC, and 7.1-42.6% (m. 19.2%) in ISH. HER2 is more often positive in intestinal type. HER2 detection in gastric carcinoma shows certain specific features - positive cells show either complete or basolateral membranous expression. Due to more frequent inhomogenity of tumor population, the threshold has been set at 10% of positive cells in resection specimens, but even one cohesive cluster of positive (2+ or 3+) neoplastic cells is sufficient in biopsy."@en . "1802-4475" . "Karcinom \u017Ealudku je ve sv\u011Bt\u011B druhou nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na malignitu, proto se z\u00E1jem onkolog\u016F up\u00EDn\u00E1 k hled\u00E1n\u00ED nov\u00FDch prognostick\u00FDch a prediktivn\u00EDch marker\u016F. HER2 je u karcinomu \u017Ealudku negativn\u00EDm prognostick\u00FDm faktorem sdru\u017Een\u00FDm s vy\u0161\u0161\u00ED invazivitou, metastazov\u00E1n\u00EDm do uzlin a krat\u0161\u00EDm p\u0159e\u017Eit\u00EDm, i negativn\u00EDm prediktivn\u00EDm faktorem a c\u00EDlem pro biologickou l\u00E9\u010Dbu trastuzumabem. Existuj\u00ED dv\u011B metody detekce HER2 - imunohistochemie (IHC) a in situ hybridizace (ISH). Pozitivita HER2 se u karcinomu \u017Ealudku pohybuje v rozmez\u00ED 6,8-34% (pr\u016Fm. 17,6%) p\u0159i stanoven\u00ED IHC, resp. 7,1 - 42,6% (pr\u016Fm. 19,2%) pomoc\u00ED ISH. HER2 je \u010Dast\u011Bji p\u0159\u00EDtomen v intestin\u00E1ln\u00EDm typu karcinomu. P\u0159i stanoven\u00ED HER2 plat\u00ED n\u011Bkter\u00E1 specifika - za pozitivn\u00ED jsou pova\u017Eov\u00E1ny bu\u0148ky s kompletn\u00ED i s bazolater\u00E1ln\u00ED expres\u00ED proteinu, vzhledem k \u010Dast\u011Bj\u0161\u00ED nehomogenn\u00ED expresi je doln\u00ED hranice v resek\u00E1tech 10 % pozitivn\u00EDch bun\u011Bk, ale u endobioptick\u00FDch vzork\u016F je vy\u017Eadov\u00E1na p\u0159\u00EDtomnost alespo\u0148 jedn\u00E9 skupiny barv\u00EDc\u00EDch se (2+ nebo 3+) neoplastick\u00FDch bun\u011Bk." . . "RIV/00179906:_____/10:10077876!RIV11-MZ0-00179906" .